Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (NYSE: ZTS) is described as the world’s leading animal health company, and the ZTS news feed on Stock Titan brings together company announcements, regulatory updates and product developments that shape its story. Zoetis focuses on medicines, vaccines, diagnostics and technologies for animals, serving veterinarians, pet owners and livestock producers in over 100 countries.
News items for Zoetis often highlight its research and development activities and regulatory milestones. Recent releases include Health Canada approval for Portela (relfovetmab injection) to alleviate pain associated with osteoarthritis in cats and European Commission marketing authorization for Lenivia (izenivetmab) to reduce osteoarthritis pain in dogs. These updates illustrate Zoetis’ emphasis on monoclonal antibody therapies and long-acting pain management solutions for companion animals.
Investors can also follow financial and capital markets news, such as announcements of convertible senior notes offerings, senior notes issuances and the use of proceeds for share repurchases and capped call transactions. The company regularly reports dividends declared by its board of directors and provides quarterly and annual financial results through press releases and Form 8-K filings.
Zoetis participates in major healthcare conferences and hosts webcasts, including innovation-focused events that discuss its pipeline across chronic kidney disease, oncology, cardiology, osteoarthritis pain and dermatology. These events, along with earnings calls and conference presentations, are frequently covered in the news stream.
By monitoring the ZTS news page, readers can review product approvals, R&D updates, capital allocation decisions, credit facility arrangements and governance developments reported by Zoetis. This page can be revisited to see how new therapies, financial actions and strategic communications are disclosed over time.
Zoetis Inc (NYSE: ZTS) appointed Vanessa Broadhurst, Executive VP at Johnson & Johnson, to its Board of Directors, expanding the board from 11 to 12 members. Broadhurst brings extensive experience in consumer insights and direct-to-consumer marketing, set to enhance Zoetis' focus on pet owners. CEO Kristin Peck praised her strategic leadership and consumer healthcare expertise. Broadhurst is recognized as one of the "2022 Most Influential Black Executives in Corporate America" and will also serve on the Quality and Innovation Committee.
Zoetis Inc (NYSE:ZTS) is scheduled to host a webcast and conference call on August 4, 2022, at 8:30 a.m. ET. CEO Kristin Peck and CFO Wetteny Joseph will discuss the second quarter 2022 financial results. The public can access the live webcast via Zoetis' investor website, with a replay available post-event. Zoetis, a leader in animal health, reported $7.8 billion in revenue for 2021 and employs approximately 12,100 individuals globally.
Zoetis (NYSE:ZTS) has completed the acquisition of Basepaws, a petcare genetics company specializing in genetic testing and health risk assessments for pets. This strategic move enhances Zoetis' precision animal health portfolio, allowing for better disease detection and management for pet owners and veterinarians. Financial details of the acquisition were not disclosed. Zoetis aims to leverage Basepaws' insights for future innovations in petcare, supporting their commitment to advancing animal health.
Zoetis (NYSE:ZTS), the global leader in animal health, announced participation in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022. Wetteny Joseph, CFO, will present at 4:20 p.m. ET. Investors can access a live audio webcast at investor.zoetis.com/events-presentations. A replay will be available post-event. In 2021, Zoetis generated revenue of $7.8 billion, employing approximately 12,100 staff worldwide, showcasing its commitment to advancing animal care.
Summary not available.
Zoetis Inc. (NYSE:ZTS) announced the acquisition of Basepaws, a petcare genetics company known for its genetic testing and health risk assessments for cats. This strategic move aims to enhance Zoetis’ precision animal health portfolio and R&D capabilities, leveraging Basepaws’ extensive genomic and microbiome databases. Financial details of the acquisition were not disclosed. The partnership is expected to boost innovation in petcare, improving health management and overall quality of care for pets.
Zoetis (NYSE:ZTS) will participate in the Stifel 2022 Jaws and Paws Conference on June 1, 2022, with Glenn David, Executive Vice President, presenting at 4:10 p.m. ET. Investors can access a live audio webcast of the presentation through the company's investor relations website, where a replay will also be available. Zoetis is a leading animal health company, generating $7.8 billion in revenue in 2021, focused on advancing animal care worldwide. The company operates in over 100 countries with a dedicated workforce of approximately 12,100 employees.
Zoetis Inc. (NYSE:ZTS) has declared a quarterly dividend of $0.325 per share, scheduled for payment on September 1, 2022. Shareholders on record as of July 21, 2022, will receive this dividend. Zoetis remains a leader in animal health, generating $7.8 billion in revenue in 2021 with a robust workforce of approximately 12,100 employees. The company emphasizes its commitment to advancing care for animals across over 100 countries.
Zoetis reported Q1 2022 revenue of $2.0 billion, up 6% year-over-year, and net income of $595 million, reflecting a 6% increase. Adjusted net income reached $625 million, or $1.32 per diluted share, representing a 4% rise. Operationally, revenue grew 9% and adjusted net income 8%, excluding foreign exchange impacts. The company updated its full-year revenue guidance to $8.225 - $8.375 billion primarily due to unfavorable foreign exchange rates. Despite uncertainties from global challenges, Zoetis remains confident in its operational growth.
The Zoetis Foundation announced a commitment of $4.9 million to support 20 initiatives across Africa, Brazil, China, Ukraine, and the U.S. The funds will enhance veterinary scholarships, diversity programming, and mental wellness, while also aiding livestock farmers and relief efforts in Ukraine. An initial donation of $150,000 has been made to the Red Cross, with a matching commitment of up to $150,000 for colleague donations. The Foundation aims to improve livelihoods, education, and mental health support for veterinarians and farmers, backed by an overall $35 million commitment through 2025.